Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Siddhartha S. Mitra
Observed names:
S. Mitra,
Siddhartha Mitra,
Siddhartha S Mitra
Institutions:
Morgan Adams Foundation,
Children's Hospital Colorado,
University of Colorado Anschutz
Observed institutions:
Five Prime Therapeutics (United States),
Morgan Adams Foundation,
Children's Hospital Colorado,
Hospices Civils de Lyon,
Hôpital Lyon Sud,
Stanford Medicine,
Gilead Sciences (United States),
University of Colorado Anschutz,
University of Colorado Denver,
Stanford University
show all 10
ORCID:
0000-0003-3967-1496
Observed ORCID:
0000-0003-3967-1496
OpenAlex ID:
A5006303593
A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia
2015
·
Susan M. O'Brien
, Nicole Lamanna
, et al.
·
Blood
·
261
PDF
Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia
2019
·
Jeff P. Sharman
, Steven E. Coutre
, et al.
·
Journal of Clinical Oncology
·
235
Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT).
2021
·
Zev A. Wainberg
, Peter C. Enzinger
, et al.
·
Journal of Clinical Oncology
·
78
Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia
2020
·
Alexey V. Danilov
, Charles Herbaux
, et al.
·
Clinical Cancer Research
·
63
Long-term follow-up of patients with CLL treated with the selective Bruton’s tyrosine kinase inhibitor ONO/GS-4059
2017
·
Harriet S. Walter
, Sandrine Jayne
, et al.
·
Blood
·
55
Phase II study of idelalisib, a selective inhibitor of PI3Kδ, for relapsed/refractory classical Hodgkin lymphoma
2017
·
A.K. Gopal
, M.A. Fanale
, et al.
·
Annals of Oncology
·
50
FIGHT: A randomized, double-blind, placebo-controlled, phase II study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2b+ advanced gastric/gastroesophageal junction adenocarcinoma (GC).
2021
·
Daniel V.T. Catenacci
, Yoon-Koo Kang
, et al.
·
Journal of Clinical Oncology
·
37
Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton’s tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059)
2019
·
Simon A. Rule
, Guillaume Cartron
, et al.
·
Leukemia
·
24
PDF
Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
2018
·
Steven E. Coutre
, Ian W. Flinn
, et al.
·
HemaSphere
·
16
Phase I results from the phase 1/3 FIGHT study evaluating bemarituzumab and mFOLFOX6 in advanced gastric/GEJ cancer (GC).
2019
·
Mohamedtaki Abdulaziz Tejani
, Eric Cheung
, et al.
·
Journal of Clinical Oncology
·
13
Updated Results on the Clinical Activity of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Patients with CLL Previously Treated with an Inhibitor of the B-Cell Receptor Signaling Pathway
2016
·
Jeffrey P. Sharman
, Andrei R. Shustov
, et al.
·
Blood
·
6
Clinical Activity of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Patients with CLL Previously Treated with an Inhibitor of B-Cell Receptor Pathway Signaling
2015
·
Jeff P. Sharman
, Andrei R. Shustov
, et al.
·
Blood
·
3
Long-Term Follow-up with GS-4059, a Selective Irreversible BTK Inhibitor, in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia
2016
·
Harriet S. Walter
, Sandrine Jayne
, et al.
·
Blood
·
2
Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib Alone or in Combination with Idelalisib or Entospletinib in Patients with Previously Treated Chronic Lymphocytic Leukemia
2018
·
Alexey V Danilov
, Charles Herbaux
, et al.
·
Blood
·
1
Abstract 4082: Time- and exposure-dependent pharmacodynamic changes induced by the BTK inhibitor GS-4059 in healthy subjects
2017
·
Juliane M. Jürgensmeier
, Hoa Truong
, et al.
·
Cancer Research
·
1
Preliminary Results of a Phase 1b Study of Tirabrutinib (gs‐4059/ono‐4059) in Combination With Entospletinib in Patients With B‐cell Malignancies
2017
·
F. Morschhauser
, A.V. Danilov
, et al.
·
Hematological Oncology
·
1
PDF
Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of GS-4059 in Combination with Idelalisib in Subjects with B-Cell Malignancies
2016
·
Gilles A. Salles
, Franck Morschhauser
, et al.
·
Blood
·
1
752 Phagocytosis-dependent chromatin remodeling governs macrophage activation states in pediatric and adult glioma
2026
·
Senthilnath Lakshmanachetty
, Andrew Donson
, et al.
·
Journal for ImmunoTherapy of Cancer
PDF
IMMU-05 Cell surface proteome analysis of Atypical Teratoid/Rhabdoid Tumors (ATRT) identifies CD44V6 as an immunotherapy target
2026
·
Allison Cole
, Callista Tran
, et al.
·
Neuro-Oncology
A trifecta of combining innate and adaptive checkpoint blockade
2026
·
David S Beltran-Cardona
, Siddhartha S Mitra
·
Neuro-Oncology
PDF
Supplemental Figure 3a from Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia
2023
·
Alexey V. Danilov
, Charles Herbaux
, et al.
Supplemental Figure 1 from Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia
2023
·
Alexey V. Danilov
, Charles Herbaux
, et al.
PDF
Supplemental Figure 3b from Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia
2023
·
Alexey V. Danilov
, Charles Herbaux
, et al.
Data from Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia
2023
·
Alexey V. Danilov
, Charles Herbaux
, et al.
Supplementary Data from Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia
2023
·
Alexey V. Danilov
, Charles Herbaux
, et al.
PDF
Show more works
View as search
Works count:
33
Citation count:
847
H-index:
10
I10-index:
10
Year
Topic
Type